In a report released today, Stephen Willey from Stifel Nicolaus reiterated a Buy rating on Achaogen (NASDAQ: AKAO), with a price target of $14. The company’s shares closed yesterday at $7.05, close to its 52-week low of $6.23.
According to TipRanks.com, Willey is a 5-star analyst with an average return of 21.5% and a 50.7% success rate. Willey covers the Healthcare sector, focusing on stocks such as Alexion Pharmaceuticals, Lexicon Pharmaceuticals, and Akcea Therapeutics Inc.
Currently, the analyst consensus on Achaogen is a Strong Buy with an average price target of $16.20, representing a 129.8% upside. In a report issued on July 27, Mizuho Securities also reiterated a Buy rating on the stock with a $20 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $19.74 and a one-year low of $6.23. Currently, Achaogen has an average volume of 1.12M.
Based on the recent corporate insider activity of 38 insiders, corporate insider sentiment is neutral on the stock. Most recently, in June 2018, Kenneth Hillan, the President of Achaogen and President of R&D of AKAO bought 177,935 shares for a total of $1,084,807.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Achaogen, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of antibacterial treatments for multi-drug resistant (MDR) gram-negative infections. It offers Plazomicin to treat bacterial illness, such as complicated urinary tract infection, blood stream infections, and other infections due to MDR Enterobacteriaceae. The company was founded by Nathaniel E. David in June 2002 and is headquartered in South San Francisco, CA.
Read More on AKAO:
